Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma

Inclusion Criteria:

* Joined the study voluntarily and signed informed consent form;
* Age 18-75；ECOG 0-2
* Esophageal squamous cell carcinoma , radical surgery ≤3 months,R0 resection. The operative incision healed well.
* T3-4N0M0, T1-4N1-3M0 (according to AJCC2009)
* No radiotherapy, chemotherapy or other treatments pre(post)surgery
* PS ECOG 0-2
* Life expectancy of more than 3 months
* Hemoglobin(Hb)≥9 g/dL • WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L • platelet count (Pt) ≥100x 109/L • Hepatic function: ALAT and ASAT \< 2.5 x ULN, TBIL\<1.5 x ULN • Renal function: creatinine \< 1.5 x ULN
* No immuno-deficiency
* Use of an effective contraceptive for adults to prevent pregnancy.

Exclusion Criteria:

* Complete esophageal obstruction after surgery, Esophageal perforation, Haematemesis
* Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ, who survived with no evidence disease for over 3 years
* Participation in other interventional clinical trials within 30 days
* Pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives
* Drug addiction, Alcoholism or AIDS
* Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior
* Unsuitable to be enrolled in the trial in the opinion of the investigators